RIEMSER Pharma

Riemser Pharma GmbH was established in 1992 and emerged from the Friedrich Löffler Institute on Riems Island (Greifswald). RIEMSER has been in business for more than 25 years, during which it has evolved from a manufacturer of veterinary medicines to a successful provider of specialty pharmaceuticals for therapeutic niches in the field of human medicine. RIEMSER sells, licenses, markets and distributes pharmaceutical products. Over 400 approvals worldwide, of which 28 took place in the last three years, are a testament to the special expertise of RIEMSER for the approval and opening of new markets for pharmaceutical products. The product range especially covers prescription drugs to treat serious diseases in the therapeutic areas of oncology, infectiology, neurology, in the cardiovascular field, in dermatology, rheumatology, tuberculosis treatment, for the treatment of obesity and primary axillary hyperhidrosis. Medicinal products and food supplements complement the portfolio. Besides its international group headquarters in Berlin, the company has three locations in Germany. In 2014 and 2015 RIEMSER acquired the subsidiaries Keocyt based in France and Intrapharm based in England. In addition, it has established an international distribution network. RIEMSER is a portfolio company of Ardian, one of the world's leading private investment companies.